- Home
- MGRM vs SAVA Comparison
MGRM vs SAVA Comparison
Compare MGRM & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRM
- SAVA
- Stock Information
- Founded
- MGRM 2016
- SAVA 1998
- Country
- MGRM United States
- SAVA United States
- Employees
- MGRM N/A
- SAVA N/A
- Industry
- MGRM Medical/Dental Instruments
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- MGRM Health Care
- SAVA Health Care
- Exchange
- MGRM Nasdaq
- SAVA Nasdaq
- Market Cap
- MGRM 79.9M
- SAVA 70.5M
- IPO Year
- MGRM N/A
- SAVA N/A
- Fundamental
- Price
- MGRM $2.41
- SAVA $2.13
- Analyst Decision
- MGRM Strong Buy
- SAVA Buy
- Analyst Count
- MGRM 1
- SAVA 3
- Target Price
- MGRM $5.40
- SAVA $54.50
- AVG Volume (30 Days)
- MGRM 74.2K
- SAVA 1.2M
- Earning Date
- MGRM 05-14-2025
- SAVA 05-08-2025
- Dividend Yield
- MGRM N/A
- SAVA N/A
- EPS Growth
- MGRM N/A
- SAVA N/A
- EPS
- MGRM N/A
- SAVA N/A
- Revenue
- MGRM N/A
- SAVA N/A
- Revenue This Year
- MGRM N/A
- SAVA N/A
- Revenue Next Year
- MGRM N/A
- SAVA N/A
- P/E Ratio
- MGRM N/A
- SAVA N/A
- Revenue Growth
- MGRM N/A
- SAVA N/A
- 52 Week Low
- MGRM $1.92
- SAVA $1.15
- 52 Week High
- MGRM $4.21
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- MGRM 38.50
- SAVA 61.51
- Support Level
- MGRM $2.54
- SAVA $1.96
- Resistance Level
- MGRM $2.69
- SAVA $2.22
- Average True Range (ATR)
- MGRM 0.19
- SAVA 0.16
- MACD
- MGRM -0.03
- SAVA 0.01
- Stochastic Oscillator
- MGRM 18.00
- SAVA 64.81
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.